Do analysts recommend BLFS or STVN?

BioLife Solutions presently has a consensus price target of $31.38, indicating a potential downside of 16.87%. Given BioLife Solutions' higher probable upside, equities research analysts clearly believe BioLife Solutions is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLife Solutions 0 Sell rating(s) 10 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.09 Stevanato Group 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.86

Does the media refer more to BLFS or STVN?

In the previous week, BioLife Solutions had 3 more articles in the media than Stevanato Group. MarketBeat recorded 4 mentions for BioLife Solutions and 1 mentions for Stevanato Group. BioLife Solutions' average media sentiment score of 1.30 beat Stevanato Group's score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SHC or BLFS?

In the previous week, BioLife Solutions had 2 more articles in the media than Sotera Health. MarketBeat recorded 4 mentions for BioLife Solutions and 2 mentions for Sotera Health. BioLife Solutions' average media sentiment score of 1.30 beat Sotera Health's score of 0.58 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ADPT or BLFS?

In the previous week, Adaptive Biotechnologies had 13 more articles in the media than BioLife Solutions. MarketBeat recorded 17 mentions for Adaptive Biotechnologies and 4 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.30 beat Adaptive Biotechnologies' score of 0.53 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MRVI or BLFS?

In the previous week, BioLife Solutions had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 4 mentions for BioLife Solutions and 2 mentions for Maravai LifeSciences. BioLife Solutions' average media sentiment score of 1.30 beat Maravai LifeSciences' score of 0.31 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioLife Solutions 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioLife Solutions (BLFS) Competitors

$37.74 -0.33 (-0.87%)

Closing price 04:00 PM Eastern

Extended Trading

$37.73 -0.01 (-0.03%)

As of 07:30 PM Eastern

Compare

BLFS vs. STVN, SHC, ADPT, ALMR, and MRVI

Should you buy BioLife Solutions stock or one of its competitors? BioLife Solutions's main competitors and comparable companies include Stevanato Group (STVN), Sotera Health (SHC), Adaptive Biotechnologies (ADPT), Alamar Biosciences (ALMR), and Maravai LifeSciences (MRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does BioLife Solutions compare to Stevanato Group?

BioLife Solutions (NASDAQ:BLFS) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

93.2% of BioLife Solutions shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BioLife Solutions presently has a consensus price target of $31.38, indicating a potential downside of 16.87%. Given BioLife Solutions' higher probable upside, equities research analysts clearly believe BioLife Solutions is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09
Stevanato Group	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.86

BioLife Solutions has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Stevanato Group has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	19.19	-$4.59M	$1.16	32.53
Stevanato Group	€1.34B	4.88	€158.21M	€0.56	38.61

BioLife Solutions has a net margin of 53.29% compared to Stevanato Group's net margin of 10.99%. Stevanato Group's return on equity of 10.43% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Stevanato Group	10.99%	10.43%	6.16%

In the previous week, BioLife Solutions had 3 more articles in the media than Stevanato Group. MarketBeat recorded 4 mentions for BioLife Solutions and 1 mentions for Stevanato Group. BioLife Solutions' average media sentiment score of 1.30 beat Stevanato Group's score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioLife Solutions beats Stevanato Group on 9 of the 17 factors compared between the two stocks.

How does BioLife Solutions compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and BioLife Solutions (NASDAQ:BLFS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Sotera Health currently has a consensus target price of $21.50, suggesting a potential upside of 17.55%. BioLife Solutions has a consensus target price of $31.38, suggesting a potential downside of 16.87%. Given Sotera Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Sotera Health is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09

Sotera Health has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market.

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 15.4% of Sotera Health shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sotera Health has higher revenue and earnings than BioLife Solutions. Sotera Health is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.49	$77.94M	$0.57	32.09
BioLife Solutions	$96.21M	19.19	-$4.59M	$1.16	32.53

BioLife Solutions has a net margin of 53.29% compared to Sotera Health's net margin of 13.44%. Sotera Health's return on equity of 40.12% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	13.44%	40.12%	7.55%
BioLife Solutions	53.29%	2.70%	2.49%

In the previous week, BioLife Solutions had 2 more articles in the media than Sotera Health. MarketBeat recorded 4 mentions for BioLife Solutions and 2 mentions for Sotera Health. BioLife Solutions' average media sentiment score of 1.30 beat Sotera Health's score of 0.58 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLife Solutions	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sotera Health and BioLife Solutions tied by winning 8 of the 16 factors compared between the two stocks.

How does BioLife Solutions compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and BioLife Solutions (NASDAQ:BLFS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Adaptive Biotechnologies currently has a consensus price target of $27.07, indicating a potential downside of 2.93%. BioLife Solutions has a consensus price target of $31.38, indicating a potential downside of 16.87%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Adaptive Biotechnologies is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09

Adaptive Biotechnologies has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

BioLife Solutions has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$308.08M	14.45	-$59.50M	-$0.41	N/A
BioLife Solutions	$96.21M	19.19	-$4.59M	$1.16	32.53

BioLife Solutions has a net margin of 53.29% compared to Adaptive Biotechnologies' net margin of -20.73%. BioLife Solutions' return on equity of 2.70% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
BioLife Solutions	53.29%	2.70%	2.49%

In the previous week, Adaptive Biotechnologies had 13 more articles in the media than BioLife Solutions. MarketBeat recorded 17 mentions for Adaptive Biotechnologies and 4 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.30 beat Adaptive Biotechnologies' score of 0.53 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLife Solutions	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Adaptive Biotechnologies and BioLife Solutions tied by winning 8 of the 16 factors compared between the two stocks.

How does BioLife Solutions compare to Alamar Biosciences?

BioLife Solutions (NASDAQ:BLFS) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

93.2% of BioLife Solutions shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BioLife Solutions presently has a consensus price target of $31.38, suggesting a potential downside of 16.87%. Alamar Biosciences has a consensus price target of $31.80, suggesting a potential downside of 1.06%. Given Alamar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Alamar Biosciences is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

BioLife Solutions has a net margin of 53.29% compared to Alamar Biosciences' net margin of 0.00%. BioLife Solutions' return on equity of 2.70% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Alamar Biosciences	N/A	N/A	N/A

In the previous week, BioLife Solutions had 4 more articles in the media than Alamar Biosciences. MarketBeat recorded 4 mentions for BioLife Solutions and 0 mentions for Alamar Biosciences. BioLife Solutions' average media sentiment score of 1.30 beat Alamar Biosciences' score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
BioLife Solutions	Positive
Alamar Biosciences	Neutral

BioLife Solutions has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	19.19	-$4.59M	$1.16	32.53
Alamar Biosciences	$74.21M	30.05	-$29.82M	-$1.96	N/A

Summary

BioLife Solutions beats Alamar Biosciences on 11 of the 15 factors compared between the two stocks.

How does BioLife Solutions compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

In the previous week, BioLife Solutions had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 4 mentions for BioLife Solutions and 2 mentions for Maravai LifeSciences. BioLife Solutions' average media sentiment score of 1.30 beat Maravai LifeSciences' score of 0.31 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLife Solutions	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioLife Solutions has a net margin of 53.29% compared to Maravai LifeSciences' net margin of -37.07%. BioLife Solutions' return on equity of 2.70% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
BioLife Solutions	53.29%	2.70%	2.49%

Maravai LifeSciences currently has a consensus price target of $6.83, suggesting a potential downside of 7.28%. BioLife Solutions has a consensus price target of $31.38, suggesting a potential downside of 16.87%. Given Maravai LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioLife Solutions has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	10.30	-$130.77M	-$0.52	N/A
BioLife Solutions	$96.21M	19.19	-$4.59M	$1.16	32.53

Maravai LifeSciences has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market.

Summary

BioLife Solutions beats Maravai LifeSciences on 11 of the 16 factors compared between the two stocks.

Get BioLife Solutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLFS vs. The Competition

Export

Metric	BioLife Solutions	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.85B	$10.52B	$7.21B	$13.10B
Dividend Yield	N/A	1.45%	2.53%	13.00%
P/E Ratio	32.53	73.29	274.58	25.69
Price / Sales	19.19	108.39	648.78	85.88
Price / Cash	162.37	27.60	76.31	52.02
Price / Book	4.89	5.82	10.44	6.32
Net Income	-$4.59M	$56.67B	$3.49B	$359.73M
7 Day Performance	4.51%	4.39%	0.51%	1.35%
1 Month Performance	1.73%	2.47%	-3.38%	-3.68%
1 Year Performance	52.48%	28.33%	16.04%	5.56%

BioLife Solutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLFS BioLife Solutions	2.5561 of 5 stars	$37.74 -0.9%	$31.38 -16.9%	+50.6%	$1.85B	$96.21M	32.53	155	News Coverage Positive News Analyst Downgrade
STVN Stevanato Group	2.1157 of 5 stars	€21.67 +1.6%	N/A	-19.7%	€6.56B	€1.23B	38.69	6,010
SHC Sotera Health	3.9809 of 5 stars	$18.87 +1.9%	$21.50 +14.0%	+15.8%	$5.39B	$1.22B	33.12	3,000	Positive News
ADPT Adaptive Biotechnologies	1.8988 of 5 stars	$25.22 +1.8%	$24.42 -3.2%	+101.3%	$4.02B	$276.98M	N/A	624	Analyst Forecast
ALMR Alamar Biosciences	1.1219 of 5 stars	$28.40 +1.5%	$31.80 +12.0%	N/A	$1.97B	$100.42M	N/A	222

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLFS) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLife Solutions (BLFS) Competitors

BLFS vs. STVN, SHC, ADPT, ALMR, and MRVI

How does BioLife Solutions compare to Stevanato Group?

Summary

How does BioLife Solutions compare to Sotera Health?

Summary

How does BioLife Solutions compare to Adaptive Biotechnologies?

Summary

How does BioLife Solutions compare to Alamar Biosciences?

Summary

How does BioLife Solutions compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS vs. The Competition

BioLife Solutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLife Solutions (BLFS) Competitors

BLFS vs. STVN, SHC, ADPT, ALMR, and MRVI

How does BioLife Solutions compare to Stevanato Group?

Do insiders and institutionals have more ownership in BLFS or STVN?

Do analysts recommend BLFS or STVN?

Which has more volatility and risk, BLFS or STVN?

Which has stronger valuation & earnings, BLFS or STVN?

Is BLFS or STVN more profitable?

Does the media refer more to BLFS or STVN?

Summary

How does BioLife Solutions compare to Sotera Health?

Do analysts prefer SHC or BLFS?

Which has more risk and volatility, SHC or BLFS?

Do institutionals and insiders hold more shares of SHC or BLFS?

Which has stronger earnings & valuation, SHC or BLFS?

Is SHC or BLFS more profitable?

Does the media favor SHC or BLFS?

Summary

How does BioLife Solutions compare to Adaptive Biotechnologies?

Do analysts recommend ADPT or BLFS?

Which has more risk and volatility, ADPT or BLFS?

Which has stronger valuation & earnings, ADPT or BLFS?

Is ADPT or BLFS more profitable?

Does the media favor ADPT or BLFS?

Do insiders & institutionals believe in ADPT or BLFS?

Summary

How does BioLife Solutions compare to Alamar Biosciences?

Do insiders and institutionals hold more shares of BLFS or ALMR?

Do analysts rate BLFS or ALMR?

Is BLFS or ALMR more profitable?

Does the media refer more to BLFS or ALMR?

Which has higher valuation and earnings, BLFS or ALMR?

Summary

How does BioLife Solutions compare to Maravai LifeSciences?

Does the media favor MRVI or BLFS?

Is MRVI or BLFS more profitable?

Do analysts recommend MRVI or BLFS?

Do institutionals and insiders hold more shares of MRVI or BLFS?

Which has higher earnings & valuation, MRVI or BLFS?

Which has more risk and volatility, MRVI or BLFS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS vs. The Competition

BioLife Solutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools